With the first patent being granted to “BiDil,” a combined medication that is deemed to be most effective for a specific “race,” African-Americans for a specific form of heart failure, the on-going debate about the effect of the older category of race has been renewed. What role should “race” play in the discussion of genetic alleles and populations today?    The new genetics has seemed to make “race” both a category that is seen useful if not necessary, as The New York Times noted recently: "Race-based prescribing makes sense only as a temporary measure." (Editorial, “Toward the First Racial Medicine,” November 13, 2004) Should one think about “race” as a transitional category that is of some use while we continue to explore the actual genetic makeup and relationships in populations? Or is such a transitional solution poisoning the actual research and practice.
Does “race” present both epidemiological and a historical problem for the society in which it is raised as well as for medical research and practice?  Who defines “race”? The self-defined group, the government, the research funder, the researcher? What does one do with what are deemed “race” specific diseases such as “Jewish genetic diseases” that are so defined because they are often concentrated in a group but are also found beyond the group?  Are we comfortable designating “Jews” or “African-Americans” as “races” given their genetic diversity?  The book answers these questions from a bio-medical and social perspective.
This book was previously published as a special issue of Patterns of Prejudice.